NCT05586672 (EE-TSA-LANG) is a clinical trial of EEG-HR in Autism Spectrum Disorder, sponsored by Etablissement Public de Santé Barthélemy Durand.

Who is sponsoring NCT05586672?

NCT05586672 is sponsored by Etablissement Public de Santé Barthélemy Durand.

What drugs are being tested in NCT05586672?

Interventions in NCT05586672: EEG-HR, ADI-R, ADOS-2, IDE, MSEL, Dunn.

What condition does NCT05586672 study?

NCT05586672 studies Autism Spectrum Disorder, Language Development, Neurocognitive Disorders, Child Language.

Is NCT05586672 still recruiting?

NCT05586672 is currently not yet recruiting. Last updated 19 October 2022.

Last reviewed 2022-10-19 · How we verify

NCT05586672: EE-TSA-LANG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HR-EEG Contribution in Prognostic Evaluation of Language Development in Children With ASD

Not yet recruiting Last updated 19 October 2022

What this trial tests

trial testing EEG-HR in Autism Spectrum Disorder in 120 participants. Not yet recruiting.

Timeline

2 January 2023

Primary endpoint
31 January 2027

30 June 2028

Quick facts

Lead sponsor	Etablissement Public de Santé Barthélemy Durand
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	120
Start date	2 January 2023
Primary completion	31 January 2027
Estimated completion	30 June 2028
Sites	1 location across France

Drugs / interventions tested

EEG-HR
ADI-R
ADOS-2
IDE
MSEL
Dunn

Conditions studied

Autism Spectrum Disorder — all drugs for Autism Spectrum Disorder →
Language Development — all drugs for Language Development →
Neurocognitive Disorders — all drugs for Neurocognitive Disorders →
Child Language — all drugs for Child Language →

Sponsor

Etablissement Public de Santé Barthélemy Durand — full company profile →

Who can join

Adults 3 to 4, any sex, with Autism Spectrum Disorder or Language Development. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this prospective observational multicentric cohort study is to evaluate the clinical prognostic value of the speech tracking score of language development in children with ASD aged from 3 years to 4 years and half at inclusion. Participants will followed during 4 years with an annual visit. During these visits, each participant will be clinically evaluated (scales and tests) and performed an EEG-HR recording. Two groups will be formed, one with children diagnosed with ASD with language delay, and a control group composed of non-ASD children without language delay, matched on age and gender with the ASD group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

NCT07324057 — The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavi · NA · recruiting
NCT07493096 — Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disor · recruiting
NCT07505290 — Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial f · NA · active not recruiting
NCT07524192 — A Self-Instructional Online Program for Early Childhood and Elementary Teachers Supporting Autistic Children and Childre · NA · recruiting
NCT07432776 — Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design · EARLY_PHASE1 · recruiting

Other Etablissement Public de Santé Barthélemy Durand trials

Trials by the same sponsor.

NCT07191691 — Observational Study of Psychomotor Development in Children Born in France to Parents Born in Sub-Saharan Africa. · not yet recruiting
NCT05583240 — Influence of Olfaction Essential Oils on the Consumption of Benzodiazepine Receptor Agonists & Z-Drugs (BZRAs) Prescribe · Phase 4 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05586672 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Etablissement Public de Santé Barthélemy Durand
Last refreshed: 19 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05586672.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing